FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754910468> ?p ?o ?g. }

• W2754910468 abstract "Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to understand antifibrotic prescribing and identify unmet needs in IPF treatment practice. Between February and March 2016, respiratory physicians from France, Germany, Italy, Spain, and the UK participated in an online questionnaire designed to collect information on IPF treatment patterns in patients under their care. Patients were categorized as treated (received approved antifibrotics) or untreated (did not receive approved antifibrotics, but may have received other unapproved therapies). Classification of IPF diagnosis (confirmed/suspected) and severity (‘mild’/‘moderate’/‘severe’) for each patient was based on the individual physician’s report. Patients’ perspectives were not recorded in this study. In total, 290 physicians responded to the questionnaire. Overall, 54% of patients with IPF did not receive treatment with an approved antifibrotic. More patients had a confirmed IPF diagnosis in the treated (84%) versus the untreated (51%) population. Of patients with a confirmed diagnosis, 40% did not receive treatment. The treated population was younger than the untreated population (67 vs 70 years, respectively; p ≤ 0.01), with more frequent multidisciplinary team evaluation (83% vs 57%, respectively; p ≤ 0.01). A higher proportion of untreated patients had forced vital capacity > 80% at diagnosis versus treated patients. Of patients with ‘mild’ IPF, 71% did not receive an approved antifibrotic versus 41% and 60% of patients with ‘moderate’ and ‘severe’ IPF, respectively. Despite the availability of antifibrotic therapies, many European patients with confirmed IPF do not receive approved antifibrotic treatment. Importantly, there appears to be a reluctance to treat patients with ‘mild’ or ‘stable’ disease, and instead adopt a ‘watch and wait’ approach. More education is required to address diagnostic uncertainty, poor understanding of IPF and its treatments, and issues of treatment access. There is a need to increase physician awareness of the benefits associated with antifibrotic treatment across the spectrum of IPF severity." @default.
• W2754910468 created "2017-09-25" @default.
• W2754910468 creator A5012539336 @default.
• W2754910468 creator A5036924296 @default.
• W2754910468 creator A5038615410 @default.
• W2754910468 creator A5041369932 @default.
• W2754910468 creator A5045956987 @default.
• W2754910468 creator A5055981872 @default.
• W2754910468 creator A5058325633 @default.
• W2754910468 creator A5070498798 @default.
• W2754910468 date "2017-09-15" @default.
• W2754910468 modified "2023-10-07" @default.
• W2754910468 title "Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries" @default.
• W2754910468 cites W1757222072 @default.
• W2754910468 cites W1938547050 @default.
• W2754910468 cites W1963595950 @default.
• W2754910468 cites W1994836525 @default.
• W2754910468 cites W2004697839 @default.
• W2754910468 cites W2011826235 @default.
• W2754910468 cites W2032982058 @default.
• W2754910468 cites W2057292199 @default.
• W2754910468 cites W2076914293 @default.
• W2754910468 cites W2077341225 @default.
• W2754910468 cites W2104766198 @default.
• W2754910468 cites W2107723678 @default.
• W2754910468 cites W2109004596 @default.
• W2754910468 cites W2114970103 @default.
• W2754910468 cites W2117488044 @default.
• W2754910468 cites W2119214281 @default.
• W2754910468 cites W2120511507 @default.
• W2754910468 cites W2122808445 @default.
• W2754910468 cites W2129520400 @default.
• W2754910468 cites W2138784721 @default.
• W2754910468 cites W2138871107 @default.
• W2754910468 cites W2140793587 @default.
• W2754910468 cites W2141997945 @default.
• W2754910468 cites W2143924572 @default.
• W2754910468 cites W2167383172 @default.
• W2754910468 cites W2168666423 @default.
• W2754910468 cites W2194918651 @default.
• W2754910468 cites W2208096782 @default.
• W2754910468 cites W2226107176 @default.
• W2754910468 cites W2234776864 @default.
• W2754910468 cites W2235523093 @default.
• W2754910468 cites W2256923448 @default.
• W2754910468 cites W2295461102 @default.
• W2754910468 cites W2394742651 @default.
• W2754910468 cites W2465306487 @default.
• W2754910468 cites W2485988367 @default.
• W2754910468 cites W2524005801 @default.
• W2754910468 cites W2540809041 @default.
• W2754910468 cites W2626588662 @default.
• W2754910468 cites W2768365177 @default.
• W2754910468 doi "https://doi.org/10.1186/s12890-017-0468-5" @default.
• W2754910468 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5602932" @default.
• W2754910468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28915874" @default.
• W2754910468 hasPublicationYear "2017" @default.
• W2754910468 type Work @default.
• W2754910468 sameAs 2754910468 @default.
• W2754910468 citedByCount "69" @default.
• W2754910468 countsByYear W27549104682018 @default.
• W2754910468 countsByYear W27549104682019 @default.
• W2754910468 countsByYear W27549104682020 @default.
• W2754910468 countsByYear W27549104682021 @default.
• W2754910468 countsByYear W27549104682022 @default.
• W2754910468 countsByYear W27549104682023 @default.
• W2754910468 crossrefType "journal-article" @default.
• W2754910468 hasAuthorship W2754910468A5012539336 @default.
• W2754910468 hasAuthorship W2754910468A5036924296 @default.
• W2754910468 hasAuthorship W2754910468A5038615410 @default.
• W2754910468 hasAuthorship W2754910468A5041369932 @default.
• W2754910468 hasAuthorship W2754910468A5045956987 @default.
• W2754910468 hasAuthorship W2754910468A5055981872 @default.
• W2754910468 hasAuthorship W2754910468A5058325633 @default.
• W2754910468 hasAuthorship W2754910468A5070498798 @default.
• W2754910468 hasBestOaLocation W27549104681 @default.
• W2754910468 hasConcept C126322002 @default.
• W2754910468 hasConcept C2777714996 @default.
• W2754910468 hasConcept C2778341716 @default.
• W2754910468 hasConcept C2779832356 @default.
• W2754910468 hasConcept C2780171596 @default.
• W2754910468 hasConcept C2908647359 @default.
• W2754910468 hasConcept C71924100 @default.
• W2754910468 hasConcept C99454951 @default.
• W2754910468 hasConceptScore W2754910468C126322002 @default.
• W2754910468 hasConceptScore W2754910468C2777714996 @default.
• W2754910468 hasConceptScore W2754910468C2778341716 @default.
• W2754910468 hasConceptScore W2754910468C2779832356 @default.
• W2754910468 hasConceptScore W2754910468C2780171596 @default.
• W2754910468 hasConceptScore W2754910468C2908647359 @default.
• W2754910468 hasConceptScore W2754910468C71924100 @default.
• W2754910468 hasConceptScore W2754910468C99454951 @default.
• W2754910468 hasIssue "1" @default.
• W2754910468 hasLocation W27549104681 @default.
• W2754910468 hasLocation W27549104682 @default.
• W2754910468 hasLocation W27549104683 @default.
• W2754910468 hasLocation W27549104684 @default.
• W2754910468 hasLocation W27549104685 @default.
• W2754910468 hasLocation W27549104686 @default.
• W2754910468 hasLocation W27549104687 @default.

• next